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Introduction
Women with gestational diabetes mellitus (GDM) have an increased risk of both adverse obstetrical outcomes, mainly related to a large birth size of the newborn and subsequent development of type 2 diabetes (T2DM) [1] [2] [3] [4] . GDM pathophysiology consists of insulin resistance accompanied by impaired ␤-cell function leading to maternal hyperglycemia [5] . Consequently, increased placental glucose transfer to the fetus causes fetal hyperinsulinemia and further macrosomia [6] . The underlying and worsening ␤-cell dysfunction coupled with a background of chronic insulin resistance usually due to overweight or obesity exposes a woman to an increased risk of developing diabetes. In clinical practice, a woman who delivers a large-for-gestational-age (LGA, birth weight above the 90th percentile for gestational age) infant is more likely to have GDM and this combination is considered a risk factor for GDM in a subsequent pregnancy. However, studies focusing on T2DM risk in women with a history of LGA birth (but without GDM) have given conflicting results, probably due to the variation of the follow-up time, ascertainment of the cases and controls and women's overall T2DM risk profile [7] [8] [9] [10] . In other words, based on the pathophysiology of prenatal growth of LGA newborns, women with a history of an LGA infant delivery could be at an increased risk of subsequent development of diabetes. To test this hypothesis, our objective was to compare the incidence of subsequent prediabetes and T2DM in women with GDM to women without GDM in different birth size groups.
Methods
This hospital register-based cohort study included women whose pregnancies were treated in Kuopio University Hospital, Finland, in 1989-2009. Women who had the diagnosis of GDM and a random sample of normoglycemic control women, both groups with completed oral glucose tolerance test (OGTT) during pregnancy, were contacted by a letter and invited for the study. A total of 489 women with GDM and 385 controls with a normal OGTT result during pregnancy attended the follow-up study. 1234 women did not reply or refused to participate in the study. All participants gave a written informed consent.
The women with and without GDM were classified based on the birth weight of the newborn: between 10-90th percentile (appropriate-for-gestational-age; AGA) (n = 662) and over 90th percentile (LGA) (n = 116). The women without GDM and delivering a child with birth weight between 10-90th percentile served as a control group. In this study, LGA was defined as sex-specific birth weight for gestational age above the 90th percentile of the current Finnish newborn growth charts [11] .
Data collection during pregnancy
In Finland, cost-free maternity care is offered to all pregnant women. The women considered to be at risk of GDM underwent 2-h OGTT (75 g glucose after overnight fasting) between the 24th and 28th weeks of gestation if one or more following factors were present: age over 40 years, BMI ≥ 25 kg/m 2 , prior GDM or a delivery of a macrosomic infant, glucosuria, suspected fetal macrosomia in the current pregnancy. The diagnostic criteria of GDM were as follows: 
The follow-up study
The participants were recruited to the follow-up study between 2006 and 2009. The women underwent laboratory tests, body composition and blood pressure measurements, and answered to a questionnaire concerning their family history and health behavior. To study glucose tolerance, the participants underwent 2-h OGTT (75 g of glucose). T2DM was defined according to the American Diabetes Association (ADA) recommendations: fasting plasma glucose ≥7 mmol/l or 2-h plasma glucose ≥11.1 mmol/l. Fasting plasma glucose between 5.6 and 6.9 mmol/l was defined as impaired fasting plasma glucose (IFG) and 2-h plasma glucose between 7.8-11.0 as impaired glucose tolerance (IGT) [12] . Women who had been diagnosed with T2DM during the follow-up time (N = 15) did not undergo OGTT. Height was measured to the nearest 0.5 cm and weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by the height (m) squared. Waist circumference (at the midpoint between the lateral iliac crest and the lowest rib) was measured to the nearest 0.5 cm.
Laboratory determinations
Plasma glucose was measured by an enzymatic hexokinase photometric assay (Konelab Systems reagents; Thermo Fischer Scientific, Vantaa, Finland), insulin by an immunoassay (ADVIA Centaur Insulin IRI no. 02230141; Siemens Medical Solutions Diagnostics, Tarrytown, NY), and HbA1c by a high-performance liquid chromatography assay (TOSOH G7 glycohemoglobin analyzer, Tosoh Bioscience, Inc., San Francisco, CA), calibrated to direct-current current transformers (DCCT) standard.
Statistical analyses
The statistical analyses were conducted using SPSS version 19 (SPSS Inc., Chicago, IL). The results were given as the mean ± SD or number of cases and percentages. Statistical differences in categorical variables between the study groups and controls were evaluated using the 2 test. Anthropometric and biochemical continuous variables were analyzed using Student's t-test, and log-transformed variables were used to correct for their skewed distribution when appropriate. p < 0.05 was considered statistically significant. Since the diagnosis of GDM was based on slightly different criteria depending on the origin of the blood during the data collection, a correlation coefficient was used to convert all values to correspond venous plasma levels. The correlation coefficient was based on the information from the Department of Clinical Chemistry at Kuopio University Hospital. This study was approved by the local Ethics Committee of the Kuopio University Hospital in accordance with the Helsinki Declaration.
Results
The prepregnancy and peripartum characteristics of the women with and without GDM stratified according to the birth weight of the offspring are shown in Table 1 . The women with previous GDM were older and heavier in both birth weight categories than those without GDM. Parity was higher in the women with GDM and in those with an LGA delivery without GDM. The women with GDM in the AGA group had more diabetes in family history and smoked more often. Otherwise, the study groups had comparable family history of diabetes, marital, smoking and alcohol consumption status. Prior spontaneous abortion rate was higher in the women with GDM in the LGA group. The women with LGA infants had more frequently a history of a macrosomic offspring than those in the normal birth weight groups. However, prior cesarean section was more common in the women with LGA infants and absence of GDM. The women with GDM in the AGA group gained less weight during pregnancy, had shorter gestational age and lower Apgar score at delivery than the controls. The incidence of pre-eclampsia was higher in both GDM groups compared to controls. No significant difference was observed in the gender of the offspring between the subgroups.
The clinical characteristics of the study groups at the follow-up study are shown in Table 2 . The women with GDM had shorter follow-up time in both birth weight categories. As during the index pregnancy, the women with GDM were significantly heavier in both birth weight categories. However, the groups did not differ in weight gain during the follow-up time. The GDM women had higher basal glucose and insulin levels in both birth weight groups.
The incidence of prediabetes (IFG and/or IGT) and T2DM at the follow-up study according to the birth weight of the offspring is shown in Fig. 1 . During the follow-up time after the index pregnancy, the incidence of prediabetes increased in the women with and without GDM from 46.3% and 26.2% (AGA) to 52.9% and 29.2% (LGA). The incidence of T2DM was 11.8% in the GDM women and 0% in the women without GDM who had given birth to LGA infants. The incidence of T2DM in the GDM women with previous LGA delivery was significantly higher compared to the GDM women with AGA delivery as well. 
Discussion
This prospective long-term study of the women with and without GDM demonstrated that a history of an LGA infant in the absence of GDM did not predict T2DM. In contrast, 11.8% of the women with GDM and LGA infants developed T2DM during a ten-year follow-up. Moreover, the incidence of prediabetes was significantly greater in the GDM women in both birth weight categories; every other woman had prediabetes in the follow-up. Only one of four women without GDM had prediabetes when the infant's birth weight was between 10-90th percentile. Overall, the delivery of an LGA infant is predictive of maternal long-term outcomes in women with GDM but not in women with normal glucose tolerance during pregnancy. The well-known Pedersen hypothesis (1952) states that maternal hyperglycemia causes macrosomia through fetal hyperglycemia and hyperinsulinemia [6] . To date, however, it is known that a variety of factors affects infant's birth weight, such as high parity and prepregnancy overweight [13] . Especially maternal BMI has much higher impact on the prediction of an LGA delivery than the 2-h glucose level in OGTT during pregnancy [14] . This opens up a wider viewpoint reflecting the reasons behind an LGA delivery and, thus, for the consequences of an LGA delivery to the women's long-term health.
Infrequent studies exist on the association between an LGA delivery and subsequent maternal T2DM. In these studies, settings, follow-up times, ascertainment of cases and controls and LGA definitions vary substantially. To elucidate this complex ground, we performed a literature search and collected the appropriate data to Table 3 . Contrary to our study, the review suggests that the risk of T2DM after an LGA delivery is somewhat increased: pooled OR 1.26 (95% CI 0.97-1.63). Taking into account available adjusted ORs, the risk became significant: pooled OR 1.37 (95% CI 1.14-1.65) ( Table 3 ). There appeared to be a few factors affecting the results. Up to 27 years postpartum, Larsson et al. demonstrated that the incidence of T2DM had risen but this was explained by obesity and high parity [7] . Tehrani et al. included also stillbirths in the LGA study group which could have affected the results [8] . Moreover, two studies included GDM women in the study groups [15, 16] , biasing the results, whereas GDM status was carefully defined and checked in the present study. In fact, these two studies [15, 16] along with the Larsson et al.'s study [7] were the only studies suggesting significantly increased T2DM risk after an LGA delivery. The remaining previous studies [8, 10] , and our findings did not demonstrate significantly increased risk of later T2DM. In addition, a study of 18 women with LGA compared to 18 women with appropriate-for-gestational-age (AGA) infants did not find significant differences in glucose, insulin or HbA1c levels between the groups two years after pregnancy [9] . Taking together, the predictability of later T2DM after an LGA delivery depended on various factors in study settings.
The present study demonstrated that GDM women with a previous LGA delivery have a considerable risk for incident T2DM. We identified a few factors associating with an LGA delivery in the GDM women; they were older and heavier in prepregnancy, had higher parity and probably severer dysglycemia during pregnancy than the GDM women without an LGA delivery. In a previous study, we have demonstrated that women with two or more abnormal values in OGTT during pregnancy are at an increased risk for the development of T2DM [4] . Despite the fact that all the women in this study had one or more risk factors for GDM, an LGA delivery in women without GDM did not predict later T2DM. This was an interesting finding since despite clinical risks brought about by an
LGA delivery and being overweight, these women clearly had some potential protective factors against T2DM.
The strengths of the current study included the long-term follow-up of a well-characterized cohort of women, and the similar treatment received by all participants with GDM during pregnancy. It should be noted that in the present study, the GDM criteria in years 1989-2008 were tight especially regarding the fasting glucose value in OGTT. Consequently, our results indicated that the absence of T2DM in women with an LGA delivery but without GDM was genuine. The limitations of this study involved the inclusion of subjects based on a riskbased screening, which may have caused some selection bias.
In addition, the study setting was cross-sectional at the time of follow-up OGTT, not longitudinal that would have been optimal to standardize the protocol.
Conclusion
We conclude that GDM women with LGA infants are at increased risk for the subsequent development of T2DM and therefore represent a target group for intervention to delay or prevent development of T2DM. However, the findings also implied that an LGA delivery in the absence of GDM does not predict T2DM in the mean follow up time of 7.3 years. Thus, The LGA study group includes stillbirths, T2DM = type 2 diabetes mellitus, BMI=body mass index, OR=odds ratio, HR=hazard ratio.
